Loading...
XHKG
1112
Market cap1.63bUSD
Oct 09, Last price  
20.28HKD
1D
2.22%
1Q
42.02%
Jan 2017
-15.32%
IPO
84.70%
Name

Health And Happines(H&H)Intrntnl Hds Ltd

Chart & performance

D1W1MN
XHKG:1112 chart
P/E
56.94
P/S
0.78
EPS
0.30
Div yield, %
1.21%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
5.10%
Revenues
14.35b
+9.97%
558,969,0001,233,560,0002,189,034,0003,381,901,0004,561,299,0004,731,563,0004,818,561,0006,505,616,0008,095,345,00010,132,498,00010,925,217,00011,194,679,00011,547,825,00012,775,914,00013,926,470,00013,051,708,00014,353,571,000
Net income
196m
P
108,317,000265,683,000527,351,000743,106,000820,715,000806,786,000251,461,000954,396,000932,846,000843,148,0001,005,049,0001,136,694,000508,484,000611,783,000581,845,000-53,721,000196,140,000
CFO
994m
-26.15%
109,798,000381,012,000516,212,000947,182,000660,473,000972,172,000365,732,0001,543,193,0001,950,814,0001,697,212,0001,439,243,0001,532,552,0001,890,080,0001,469,313,0001,096,819,0001,346,423,000994,384,460
Dividend
Sep 10, 20260.82 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

As an investment holding entity, Health and Happiness (H&H) International Holdings Limited specializes in the global production and distribution of nutritional and care products designed for families and infants. Its offerings are categorized into several key segments. The Infant Formulas division crafts nutritional formulas for children up to age seven, alongside specialized milk products for pregnant and breastfeeding women. The Probiotic Supplements division provides various forms of probiotics, including sachets, capsules, and tablets, catering to the needs of babies, children, and expecting mothers. Within its Adult Nutrition and Care Products segment, H&H develops and markets a range of items such as vitamins, general health supplements, skincare solutions, and sports nutrition for grown-ups. Complementing its infant offerings, the Other Pediatric Products segment focuses on manufacturing dried baby foods, additional nutritional supplements, and general baby care items. Furthermore, its Pet Nutrition and Care segment creates pet food, health-enhancing supplements, and bone broth products for animals. Beyond these core product lines, the company's activities extend to research, development, and processing of diverse ingredients like meat, fruit, and vegetable powders, as well as candies. It actively researches, develops, manufactures, and sells specialized nutritional foods, manages the marketing and distribution of organic baby foods, and handles the wholesale, retail, import, and export of infant nutritional and personal care products. H&H also engages in the trading and sale of adult vitamins, health supplements, probiotic skincare, and sports nutrition items, while offering online sales platforms, software and IT solutions, and packaging services. Its extensive product portfolio is marketed under well-known brands such as Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII. Established in 1999, the company adopted its current name, Health and Happiness (H&H) International Holdings Limited, in June 2017, having previously operated as Biostime International Holdings Limited. Headquartered in Quarry Bay, Hong Kong, H&H functions as a subsidiary of Biostime Pharmaceuticals (China) Limited.

Related entities

Subsidiaries
BIOSTIME HEALTHY AUSTRALIA INVESTMENT PTY LTD

Key people

Fei Luo
Executive Chairman of the Board · since 2019
Qizhang Zhang
General Manager - New Business Development Department · since 2017
Radek Sali
Executive Director · since 2016
Yidong Wang
Chief Financial Officer, Executive Director · since 2018
Yun Luo
Non-Executive Director · since 2010
Wenhui Zhang
Non-Executive Director · since 2012
Non-Executive Independent Director · since 2010
IPO date
Dec 17, 2010
Employees
3,372
Domiciled in
HK
Incorporated in
KY
Headquarters & legal address
P. O. Box 2681
CRICKET SQUARE
HUTCHINS DRIVE
GEORGE TOWN KY1-1111
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT